TW202325744A - 用於ｈｉｖ之抗原結合多肽、抗原結合多肽複合物及其使用方法 - Google Patents

用於ｈｉｖ之抗原結合多肽、抗原結合多肽複合物及其使用方法 Download PDF

Info

Publication number
TW202325744A
TW202325744A TW111136760A TW111136760A TW202325744A TW 202325744 A TW202325744 A TW 202325744A TW 111136760 A TW111136760 A TW 111136760A TW 111136760 A TW111136760 A TW 111136760A TW 202325744 A TW202325744 A TW 202325744A
Authority
TW
Taiwan
Prior art keywords
variable region
chain variable
specifically binds
heavy chain
polypeptide
Prior art date
Application number
TW111136760A
Other languages
English (en)
Chinese (zh)
Inventor
羅尼 榮 魏
玲 許
智勇 楊
蓋瑞 Ｊ 奈博
Original Assignee
美商莫德斯醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商莫德斯醫療公司 filed Critical 美商莫德斯醫療公司
Publication of TW202325744A publication Critical patent/TW202325744A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW111136760A 2021-09-29 2022-09-28 用於ｈｉｖ之抗原結合多肽、抗原結合多肽複合物及其使用方法 TW202325744A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163249722P 2021-09-29 2021-09-29
US63/249,722 2021-09-29

Publications (1)

Publication Number Publication Date
TW202325744A true TW202325744A (zh) 2023-07-01

Family

ID=85783606

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111136760A TW202325744A (zh) 2021-09-29 2022-09-28 用於ｈｉｖ之抗原結合多肽、抗原結合多肽複合物及其使用方法

Country Status (13)

Country Link
US (1) US20250197481A1 (enExample)
EP (1) EP4408892A4 (enExample)
JP (1) JP2024537827A (enExample)
KR (1) KR20240099226A9 (enExample)
CN (1) CN118660907A (enExample)
AR (1) AR127176A1 (enExample)
AU (1) AU2022357501A1 (enExample)
CA (1) CA3232365A1 (enExample)
CL (1) CL2024000890A1 (enExample)
IL (1) IL311762A (enExample)
MX (1) MX2024003804A (enExample)
TW (1) TW202325744A (enExample)
WO (1) WO2023056315A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116574748B (zh) * 2023-07-10 2023-09-12 昆明医科大学 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
WO2025162460A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 一种轭合化合物及其制备和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
MX353382B (es) * 2012-03-01 2018-01-10 Amgen Res Munich Gmbh Moleculas de union polipeptido de larga duracion.
US9458244B2 (en) * 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
RS62437B1 (sr) * 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
CA3020633A1 (en) * 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
WO2018075564A1 (en) * 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
US12365722B2 (en) * 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
AU2019372673A1 (en) * 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白

Also Published As

Publication number Publication date
JP2024537827A (ja) 2024-10-16
KR20240099226A9 (ko) 2025-12-10
CN118660907A (zh) 2024-09-17
IL311762A (en) 2024-05-01
AU2022357501A1 (en) 2024-04-18
EP4408892A4 (en) 2025-11-19
CA3232365A1 (en) 2023-04-06
WO2023056315A1 (en) 2023-04-06
KR20240099226A (ko) 2024-06-28
AR127176A1 (es) 2023-12-27
MX2024003804A (es) 2024-06-11
EP4408892A1 (en) 2024-08-07
US20250197481A1 (en) 2025-06-19
CL2024000890A1 (es) 2024-10-11

Similar Documents

Publication Publication Date Title
AU2015295936B2 (en) Anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
US11390676B2 (en) Anti-LAG-3 antibodies and compositions
EP3414266B1 (en) Broadly neutralizing antibodies against hiv-1 and use thereof
EP3365366B1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
TW202330594A (zh) 抗原結合多肽、抗原結合多肽複合物及其使用方法
US20250368722A1 (en) Multispecific antibodies targeting multiple epitopes on the hiv-1 envelope
US20250179195A1 (en) Anti-flt3 antibodies and compositions
TW202334204A (zh) 條件性活化之抗原結合多肽複合物及其使用方法
US20250197481A1 (en) Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV
AU2021225490B2 (en) Anti-AXL antibodies and compositions
JP2021507717A (ja) 抗原結合性ポリペプチド
JP2025500918A (ja) Ｔｎｆｓｆリガンドの細胞外ドメインを含有する抗原結合ポリペプチド複合体
IL317895A (en) Anti-SARS-COV-2 antigen-binding polypeptides, polypeptide complexes and methods of using them
WO2025256479A1 (zh) 一种融合蛋白及其用途
WO2024123897A1 (en) Broadly neutralizing and potent antibodies against hiv
WO2026072755A2 (en) Single-chain fab proteins and uses thereof
WO2026067748A1 (zh) 靶向pd-1和4-1bb的双特异性抗体及其应用
HK1253385B (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection